Global Patent Index - EP 1225912 A4

EP 1225912 A4 20040929 - A METHOD OF PROPHYLAXIS AND TREATMENT

Title (en)

A METHOD OF PROPHYLAXIS AND TREATMENT

Title (de)

METHODE ZUR PROPHYLAXE UND BEHANDLUNG

Title (fr)

PROCEDE DE PROPHYLAXIE ET DE TRAITEMENT

Publication

EP 1225912 A4 20040929 (EN)

Application

EP 00972430 A 20001020

Priority

  • AU 0001299 W 20001020
  • AU PQ362799 A 19991022
  • AU PQ434799 A 19991126
  • AU PQ762100 A 20000519

Abstract (en)

[origin: WO0130378A1] The present invention relates generally to a method of prophylaxis and treatment of autoimmune disease conditions and agents useful for same. In a related embodiment, the present invention contemplates the use of mucosal antigens and/or agents capable of blocking or otherwise delaying cytotoxic T-lymphocyte (CTL) induction and/or maturation to prevent or at least reduce the likelihood or risk of CTL-mediated autoimmune disease. More particularly, the present invention contemplates mucosa-mediated tolerance to protect against or ameliorate the symptoms associated with autoimmune pathology. Even more particularly, the present invention provides a method for preventing clinical insulin-dependent diabetes mellitus (IDDM) or preventing or reducing or ameliorating the effects of clinical IDDM by the aerosol administration of IDDM-associated autoantigens to mucosal surfaces or agents which block CTL induction and/or maturation.

IPC 1-7

A61K 38/28; A61K 39/00; C07K 16/28; A61K 38/19; A61P 3/10; A61P 37/02

IPC 8 full level

A61K 9/12 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 3/10 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01)

CPC (source: EP)

A61K 39/0008 (2013.01); A61P 3/10 (2017.12); A61P 37/02 (2017.12); A61P 37/06 (2017.12); C07K 16/2875 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/541 (2013.01)

Citation (search report)

  • [X] WO 9626218 A1 19960829 - AMRAD OPERATIONS PTY LTD [AU], et al
  • [X] VON HERRATH M G ET AL: "In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 NOV 1998, vol. 161, no. 9, 1 November 1998 (1998-11-01), pages 5087 - 5096, XP000919064, ISSN: 0022-1767
  • [X] TIAN JIDE ET AL: "Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, no. 4, 1996, pages 1561 - 1567, XP009032068, ISSN: 0022-1007
  • [X] BIANCONE LUIGI ET AL: "Distinct regulatory roles of lymphocyte costimulatory pathways on T helper type 2-mediated autoimmune disease", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, no. 4, 1996, pages 1473 - 1481, XP002284659, ISSN: 0022-1007
  • [X] HOWARD LAURENCE M ET AL: "Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis", JOURNAL OF CLINICAL INVESTIGATION, vol. 103, no. 2, January 1999 (1999-01-01), pages 281 - 290, XP002284660, ISSN: 0021-9738
  • [X] BALASA B ET AL: "CD40 LIGAND-CD40 INTERACTIONS ARE NECESSARY FOR THE INITIATION OF INSULITIS AND DIABETES IN NONOBESE DIABETIC MICE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 159, no. 9, 1 November 1997 (1997-11-01), pages 4620 - 4627, XP001180168, ISSN: 0022-1767
  • [A] GAIRIN J E ET AL: "DESIGN OF HIGH-AFFINITY MAJOR HISTOCOMPATIBILITY COMPLEX-SPECIFIC ANTAGONIST PEPTIDES THAT INHIBIT CYTOTOXIC T-LYMPHOCYTE ACTIVITY: IMPLICATIONS FOR CONTROL OF VIRAL DISEASE", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 11, 1 November 1992 (1992-11-01), pages 6755 - 6762, XP000560304, ISSN: 0022-538X
  • [A] FALK K ET AL: "ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 351, no. 6324, 23 May 1991 (1991-05-23), pages 290 - 296, XP000310533, ISSN: 0028-0836
  • [A] RUDY G ET AL: "SIMILAR PEPTIDES FROM TW BETA CELL AUTOANTIGENS, PROINSULIN AND GLUTAMIC ACID DECARBOXYLASE, STIMULATE T CELLS OF INDIVIDUALS AT RISK FOR INSULIN-DEPENDENT DIABETES", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, 1 September 1995 (1995-09-01), pages 625 - 633, XP000607204, ISSN: 1076-1551
  • [A] MARTINEZ N R ET AL: "Mucosa-mediated tolerance to native and modified proinsulin peptide in the non-obese diabetic mouse", IMMUNOLOGY LETTERS, vol. 69, no. 1, 15 June 1999 (1999-06-15), 10th International Congress of Mucosal Imunology;Amsterdam, Netherlands; June 27-July 1, 1999, pages 84, XP002284661, ISSN: 0165-2478
  • [A] HARRISON L C ET AL: "AEROSOL INSULIN INDUCES REGULATORY CD8 GAMMADELTA T CELLS THAT PREVENT MURINE INSULIN-DEPENDENT DIABETES", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 6, no. 184, December 1996 (1996-12-01), pages 2167 - 2174, XP001070421, ISSN: 0022-1007
  • [A] KONIARAS C ET AL: "Inhibition of naive class I-restricted T cells by altered peptide ligands", IMMUNOLOGY AND CELL BIOLOGY, vol. 77, no. 4, August 1999 (1999-08-01), pages 318 - 323, XP002284662, ISSN: 0818-9641
  • [A] FOEHLES J ET AL: "HUMAN PRO INSULIN 5. SYNTHESIS OF A PROTECTED PEPTIDE FRAGMENT CORRESPONDING TO THE SEQUENCE 24-45 OF THE PRO HORMONE", HOPPE-SEYLER'S ZEITSCHRIFT FUER PHYSIOLOGISCHE CHEMIE, vol. 361, no. 6, 1980, pages 849 - 856, XP009032231, ISSN: 0018-4888
  • [A] YANAIHARA N ET AL: "SYNTHESES OF C PEPTIDES AND HUMAN PRO INSULIN", DIABETES, vol. 27, no. SUPPL 1, 1978, pages 149 - 160, XP009032235, ISSN: 0012-1797
  • [PX] HANNINEN A: "Prevention of autoimmune type 1 diabetes via mucosal tolerance: Is mucosal autoantigen administration as safe and effective as it should?", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 52, no. 3, September 2000 (2000-09-01), pages 217 - 225, XP002284663, ISSN: 0300-9475
  • [T] HANNINEN ARNO ET AL: "Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity", JOURNAL OF CLINICAL INVESTIGATION, vol. 109, no. 2, January 2002 (2002-01-01), pages 261 - 267, XP002284664, ISSN: 0021-9738
  • [T] MARTINEZ N R ET AL: "DISABLING AN INTEGRAL CTL EPITOPE ALLOWS SUPPRESSION OF AUTOIMMUNE DIABETES BY INTRANASAL PROINSULIN PEPTIDE", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 111, no. 9, May 2003 (2003-05-01), pages 1365 - 1371, XP001168667, ISSN: 0021-9738
  • See references of WO 0130378A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0130378 A1 20010503; CA 2387652 A1 20010503; EP 1225912 A1 20020731; EP 1225912 A4 20040929; JP 2003512435 A 20030402

DOCDB simple family (application)

AU 0001299 W 20001020; CA 2387652 A 20001020; EP 00972430 A 20001020; JP 2001532795 A 20001020